Your session is about to expire
← Back to Search
Rho kinase inhibitor and Prostaglandin analogue
Rocklatan® Evaluation
Phase 4
Waitlist Available
Research Sponsored by Aerie Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 0 pretreatment), week 12
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial
Summary
This trial is testing if Rocklatan can better lower eye pressure in patients who are already using latanoprost-based treatments. Rocklatan works by helping fluid drain from the eye more effectively.
Eligible Conditions
- Glaucoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline (day 0 pretreatment), week 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 0 pretreatment), week 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12
Side effects data
From 2023 Phase 4 trial • 136 Patients • NCT0528339515%
Conjunctival hyperaemia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Rocklatan (Latanoprost Mono)
Rocklatan (Latanoprost +1)
Rocklatan (Latanoprost +2)
Awards & Highlights
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
1Treatment groups
Experimental Treatment
Group I: RocklatanExperimental Treatment1 Intervention
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, one drop in each eye in the evening for 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
2022
Completed Phase 4
~140
Find a Location
Who is running the clinical trial?
Aerie PharmaceuticalsLead Sponsor
38 Previous Clinical Trials
8,190 Total Patients Enrolled
25 Trials studying Glaucoma
6,269 Patients Enrolled for Glaucoma
Scientific Advisor, Clinical R&DStudy DirectorAlcon Research, LLC
Michelle S Senchyna, PhDStudy DirectorAerie Pharmaceuticals
1 Previous Clinical Trials
40 Total Patients Enrolled